Published in Hepatitis Weekly, July 18th, 2005
Civacir is Nabi Biopharmaceuticals' product candidate for the prevention of recurrent hepatitis C virus-induced liver disease in liver transplant recipients. The OMP designation will result in reduced marketing authorization application (MAA) fees, free access to scientific advice from the EMEA and other potential research and development incentives.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.